🔴 Liquidia Technologies is trading 4.1% down today after Delaware ruling finds Yutrepia patent claims infringed

Liquidia Technologies is trading at $26.52, down 4.05%, as the September 30 Delaware ruling weighs.

• The court found two United Therapeutics patent claims covering Yutrepia’s PH-ILD use valid and infringed; Liquidia plans to appeal and seek removal of the indication from the label.
• On October 2, Wells Fargo cut its rating and price target amid patent-related uncertainty.
• Biotech weakness may add pressure, but the broad market is higher and does not explain Liquidia’s decline.